Saturday, September 30, 2023
Saturday, September 30, 2023

Contact us 561.316.3330

Magnifico Open MRI System Receives FDA Approval

Magnifico Open MRI System, a new open whole-body MRI system, and now available for purchase in the USA, was designed with the user in mind through customer feedback to bridge the gap between traditional musculoskeletal imaging and whole-body imaging. 

The Magnifico Open MRI System from Esaote North America is equipped with new advanced technologies that offer versatility in imaging across a wide range of clinical applications:

  • Speed Up – Helps ensure optimal diagnostic image quality and reduce examination times.
  • True-Motion – Innovative real-time imaging solution of the joint, ideal for sports medicine injuries.
  • Metal Artifact Reduction (MAR) – Generates excellent image quality for post-surgical patients with metal implants.

“The Magnifico Open MRI System is designed for patient comfort”, says Stephen Gibbs, Manager of MRI Sales & Marketing for Esaote North America. “With an open-gantry design it is ideal for imaging children, large and claustrophobic patients. The compact size is uniquely suited for hospitals, imaging centers, and in-office clinics.”

“As MRI backlogs continue to rise, the demand for high-performance MRI is at an all-time high”, says Robert Lewis, President and General Manager of Esaote North America. “Now is the right time to bring open whole-body MRI to the US market, to help ease these scheduling challenges, while freeing up time slots on overloaded systems to accommodate more patients at the point of care.”

Drawing upon a 30-year legacy, Esaote continues to stay at the forefront, delivering cost-effective and eco-friendly diagnostic imaging solutions that meet the clinical and financial demands of customers worldwide.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy